When examining the effects of PARP inhibition, in general, and of Olaparib, in particular, one might ask how it is possible that a therapy can be beneficial as a cytostatic (in oncology) and also as a promoter of cell survival (in neurodegenerative diseases such as HD). The gene discussed is PARP1; the disease is Huntington disease.